Objective: The aim of this study was to analyze the clinical results of our adaptive radiation therapy scheme of a two-step intensity-modulated radiotherapy (IMRT) method for nasopharyngeal cancer (NPC) at Kinki University Hospital. Methods: Between 2000 and 2007, 35 patients with Stage I -IVB NPC treated by IMRT were included. For all patients, treatment-planning computed tomography was done twice before and during IMRT to a total dose of 60 -70 Gy/28 -35 fractions (median 68 Gy). Chemotherapy (cisplatin 80 mg/m 2 /3 weeks Â 1 -3 courses) was given concurrently with IMRT for 31 patients. Results: The 3-and 5-year overall survival rates for the 31 patients treated with concurrent chemotherapy were 88% and 83%, respectively. The 3-and 5-year loco-regional control rates for the 31 patients were 93% and 87%, respectively. Planning target volume delineation for the primary site or involved nodes was insufficient for three early cases, resulting in marginal recurrence in the three patients (9%). Except for one patient with early death, xerostomia scores at 1 -2 years were: Grade 0, 11; Grade 1, 17; Grade 2, 5; Grade 3, 1. Conclusions: Excellent overall survival and loco-regional control rates were obtained by a two-step IMRT method with concurrent chemotherapy for NPC, although marginal recurrence was noted in some early cases.
INTRODUCTION
For locally advanced nasopharyngeal carcinoma (NPC), concurrent chemo-radiotherapy (CRT) showed better overall survival rates compared with radiotherapy (RT) alone by several randomized clinical trials and a meta-analysis (1 -5) .
In the meta-analysis, significant benefit for overall survival and event-free survival was observed when chemotherapy was administered concomitantly with RT (1). In the randomized clinical trials comparing RT alone and concurrent CRT for locally advanced NPC, the 3-year overall survival rates were 46 -65% for RT alone and 76 -85% for CRT (2 -5) . Thus, for locally advanced NPC, concurrent CRT is regarded as a standard treatment.
Another advance in the treatment of NPC is the successful clinical use of intensity-modulated RT (IMRT). IMRT is effective especially for head and neck cancers, since the clinical target volumes (CTVs) are in contiguity with organs at risk such as the salivary glands, brain stem and spinal cord. Two randomized clinical trials comparing IMRT and conventional RT for patients with early-stage NPC showed significant benefit of IMRT on the salivary function and quality of life of patients (6, 7) . Single institutional reports on IMRT for NPC showed excellent loco-regional control rates and overall survival rates (8 -14) .
Although it is really exciting to use this new technique to improve the therapeutic ratio, questions remain whether the conformation of target coverage and normal tissue sparing may cause marginal failure (15 -17) . As treatment planning and quality assurance (QA) of IMRT plans require a long time to prepare, most investigators use the initial plan of IMRT for the whole course of IMRT. However, significant anatomic changes including shrinking of the primary tumor or nodal masses and body weight loss during fractionated RT have been reported for head and neck cancers (13, 18) . Our previous analysis revealed that the volume of the parotid glands decreased to 74% during the course of IMRT (19) . These changes in body contour, target volumes and risk organs during IMRT can affect the dose distribution to the target volume and risk organs, which can be a cause of marginal recurrence or late toxicities. In fact, marginal recurrences after IMRT for head and neck cancer are reported by several investigators (20, 21) .
To avoid the risk of changes in the dose distribution during IMRT of 7 -8 weeks, we adopted a two-step IMRT method for head and neck cancers. For all patients, treatment-planning computed tomography (CT) was done before IMRT (CT-1) and at the third or fourth week of IMRT for the treatment planning of boost IMRT after 46 -50 Gy (CT-2) (19) . In the present study, the clinical results of our adaptive RT scheme of a two-step IMRT method for patients with NPC were analyzed retrospectively.
PATIENTS AND METHODS
Between December 2000 and December 2007, 38 consecutive patients with NPC were treated at our institution. Excluding three patients with Stage IVc disease (UICC, sixth edition in 2002), 35 patients treated by IMRT were included. Patients and tumor characteristics are shown in Table 1 . Staging work-up included clinical examination, laryngo-pharyngeal fiberscope with biopsy from the primary tumors, plain chest XP, head and neck magnetic resonance imaging (MRI) and thoraco-abdominal CT scan. CT scan was performed with contrast enhancement whenever possible. After October 2005, positron emission tomography (PET) was performed for all patients, and for 14 patients, an integrated PET-CT simulation was performed at CT-1 after April 2006 (22, 23) .
Informed written consent for IMRT as a new method of RT was obtained from all patients. All 35 patients were treated by a two-step IMRT method; 34 treated with wholeneck radiotherapy to 46 -50 Gy/23 -25 fractions by IMRT, followed by boost IMRT to the high-risk CTV to a total dose of 60 -70 Gy/30 -35 fractions (median 70 Gy), and one patient treated with whole-neck radiotherapy to 44 Gy/22 fractions by a conventional method, followed by IMRT to a total dose of 70 Gy/35 fractions. The median follow-up period of the patients was 39 months with a range of 5 -94 months.
When we started IMRT in December 2000, the present institutional protocol for Stage I -IVB NPC was adopted, i.e. concurrent chemotherapy (cisplatin 80 mg/m 2 /3 weeks Â 3 courses) was given with a two-step IMRT method (70 Gy/35 fractions/7 weeks), followed by two courses of adjuvant chemotherapy (cisplatin 70 mg/m 2 , 5-fluorouracil 700 mg/m 2 Â 4 days). The dose of chemotherapy was reduced compared with the Intergroup Study 0099 because the dose used in the USA was too toxic for Japanese patients (2, 24) . For two elderly patients (.76 years old) and two patients with poor renal function, concurrent chemotherapy was not given, and they were treated with IMRT alone ( Table 2) . The remaining 31 patients were treated with concurrent chemotherapy, but the third course of concurrent chemotherapy was not administered for most patients because of acute toxicities. Although we recommended adjuvant chemotherapy for the patients, eight patients refused to receive adjuvant chemotherapy because of the toxicities associated with chemotherapy. Thus, adjuvant chemotherapy was given for 23 patients ( Table 2 ). 
TARGET DEFINITION AND DOSE SPECIFICATION
Following the recommendations of the International Commission on Radiation Units reports 50 and 62, the gross tumor volume (GTV) including the primary tumor and involved lymph nodes and CTV were determined. The definition of involved lymph nodes (GTV) was as followed. Cervical lymph nodes with the shortest axial diameter of !10 mm and retropharyngeal lymph nodes with the shortest axial diameter of !5 mm on CT or MRI were defined as malignant. Lymph nodes of borderline size with abnormal enhancement were also indications of malignancy (25, 26) . The nasopharyngeal area, bilateral Level II -V nodes and the retropharyngeal nodes were included in the initial CTV (27) . Submandibular lymph nodes (Level Ib) were only included in the CTV when involved lymph nodes were suspected in the area.
Margins of 3 -5 mm for treatment set-up and internal organ motion error were added to the CTV to determine the planning target volume (PTV) (28) . For planning organ at risk volume, a margin of 3 mm was added to the spinal cord. For the parotid glands, no margin was added in treatment planning.
After whole-neck irradiation of 44 -50 Gy in 22 -25 fractions, boost IMRT was given to the PTV2 including the GTV with appropriate margin on the basis of CT-2. The daily prescribed dose to the PTV was 2.0 Gy. The prescribed dose was normalized to the dose to 95% volume (D95) of the PTV, and the dose to 10% volume (D10) of the PTV was ,110% of the prescribed dose to the PTV (27) .
Our goals on dose -volume histogram (DVH) were PTV-max ,120% of the prescribed dose, PTV-mean ,105% (usually 103 -104%), D10 of PTV ,110%, maximum dose of the spinal cord ,48 Gy, maximum dose of the brain ,64 Gy, median dose ,19 Gy or mean dose ,25 Gy for at least one parotid gland.
TREATMENT DELIVERY AND QA IMRT was delivered using dynamic multileaf collimation with one of two linear accelerators equipped with a 40-leaf dynamic multileaf collimator (Clinac-600C, Clinac-21EX; Varian Associates). Beam energy of 4 or 6 MV X-rays was used. The daily treatment time was 15 -20 min. To verify the leaf motion of each beam, various QA performance tests were conducted. Details of QA procedures at our hospital have been described elsewhere (28, 29) .
FOLLOW-UP, SURVIVAL AND TOXICITIES
After the end of IMRT with or without adjuvant chemotherapy, loco-regional control and distant progression was evaluated every 3 -4 months for .5 years by clinical examination and laryngo-pharyngeal fiberscope, and every 6 months by head and neck MRI or CT scan and thoraco-abdominal CT scan. When tumor recurrence or distant metastasis was noted, salvage treatment was mandatory for attending physicians.
The probability of survival was estimated using the Kaplan -Meier method with statistical significance assessed by the log-rank test. Survival was calculated from the first date of RT. Overall survival considered deaths due to any cause. Progression-free survival (PFS) considered any loco-regional or distant tumor progression and any cause of deaths as events. Loco-regional control rate considered any recurrence in the primary site or regional lymph nodes as an event.
Acute and late toxicities were graded according to the Common Toxicity Criteria for Adverse Events (CTCAE), version 3.0. Although this is a retrospective analysis, grade of acute hematologic and non-hematologic toxicities were scored prospectively once a week during RT by one of two attending physicians (Y.N. and T.S.) after the start of IMRT and recorded in the clinical chart. Late toxicities on xerostomia, hearing and dysphagia were also scored prospectively and recorded in the clinical chart every 3 -4 months. In terms of xerostomia, the attending physicians asked patients on dietary alteration and necessity of a water bottle every 3 -4 months, and the best grade at 12 -24 months after the start of IMRT was recorded. Figure 1A shows overall survival rates according to concurrent chemotherapy for all the 35 patients included. The survival rate for patients treated without chemotherapy was apparently worse than that for the 31 patients treated with concurrent chemotherapy. The 3-and 5-year overall survival rates for the 31 patients treated with concurrent chemotherapy were 88% and 83%, respectively. The 5-year overall survival rates for 23 patients with Stage 1 -3 disease and 12 patients with Stage 4 disease were 73% and 62%, respectively (Fig. 1B) . As of March 2009, five patients died of
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A two-step IMRT method for NPC NPC, three patients died of intercurrent disease (pneumonia, nasal natural killer T cell lymphoma and suffocation by food) without evidence of recurrence of NPC and two patients are alive with the disease. The remaining 25 patients are alive without evidence of the disease. Figure 2A shows loco-regional control rates according to clinical stages (Stages 1 -3 vs. Stage 4). The 5-year loco-regional control rates for patients with Stage 1 -3 disease and those with Stage 4 disease were 88% and 64%, respectively, with significant difference (P ¼ 0.044). The 3-and 5-year loco-regional control rates for the 31 patients treated with concurrent chemotherapy were 93% and 87%, respectively. Figure 2B shows PFS rates according to clinical stages (Stages 1 -3 vs. Stage 4). The 5-year PFS rates for patients with Stage 1 -3 disease and those with Stage 4 disease were 73% and 29%, respectively, with significant difference (P ¼ 0.0059).
Recurrence or persistent tumors in the primary site were noted in six patients (17%). Recurrence or a persistent tumor was noted at the area of PTV receiving 60 -68 Gy in four of the six patients, whereas recurrence from the PTV margin was noted in two patients at the pterygopalatine fossa or at the posterior edge of the clivus (Fig. 3A -D) . One late recurrence at the nasopharynx was noted 66 months after chemo-IMRT (65.4 Gy/35 fractions). For this patient, second chemo-IMRT (66 Gy/30 fractions) was done and there was no evidence of the disease at 94 months after the initial IMRT without significant late toxicities.
Residual or recurrence of neck lymph nodes was noted in four patients (11%). In two patients, PTV delineation for the neck nodes was insufficient, and recurrences were noted at posterior chain lymph nodes and at a periparotid lymph node (Figs 3E -F and 4A -D). As both the primary site and neck node recurrence were noted in one patient (Fig. 3) , the PTV marginal recurrence was noted in three patients (9%). In two of the three patients with marginal recurrences, keen review of the pretreatment MRI or CT scan of the patients showed the involved nodes or the extension of the primary tumor at the edge of the PTV. In the remaining one patient, marginal recurrence was noted at the pterygopalatine fossa 3 years after chemo-IMRT. For this patient, pre-treatment MRI and CT scan did not show the tumor invasion to the pterygopalatine fossa. After February 2003, no marginal recurrence was noted at our institution. 
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A two-step IMRT method for NPC Table 3 shows the acute toxicities associated with IMRT with or without concurrent chemotherapy. Hematological toxicities were mild, and no Grade 4 hematological toxicity was noted. Two patients showed Grade 4 mucositis. One patient with Grade 4 mucositis refused CRT after 60 Gy with two doses of concurrent cisplatin, and this patient required interruption of RT for 22 days. Sepsis with high fever of Grade 4 toxicity was noted immediately after the first chemotherapy in one patient. RT was interrupted for 10 days for this patient. Except for the two patients, no treatment interruption due to acute toxicities was necessary, and the median overall treatment time was 51 days (Table 2) .
Late toxicities associated with IMRT with or without concurrent chemotherapy are shown in Table 4 . Hearing difficulty, tinnitus and otitis were common late toxicities. However, most patients with auditory toxicities had the same symptom at presentation. Although several patients complained of dysphagia after treatment, no patient needed percutaneous endoscopic gastrostomy. One patient died of suffocation by food 3 months after the end of IMRT without evidence of disease. Except for the patient with early death, xerostomia scores at 1 -2 years were: Grade 0, 11; Grade 1, 17; Grade 2, 5; Grade 3, 1. The patent with Grade 3 xerostomia was treated by conventional RT followed by boost IMRT. 
DISCUSSION
Clinical results of our adaptive RT scheme of a two-step IMRT method for NPC were analyzed in the present study, and excellent overall survival and loco-regional control rates were obtained when concurrent chemotherapy was combined with IMRT. When introducing IMRT for head and neck cancers at our hospital, we chose a most conservative method, although it is a time-consuming strategy. Inverse planning for IMRT was performed twice. This two-step IMRT method obviously took a longer time for the treatment planning and QA than a single-step simultaneous integrated boost (SIB) method which gives several dose levels for CTVs and GTV simultaneously (8, 10, 11, 14) . It took 5 working days at our institution for the inverse planning and its verification, and the IMRT plan was started 7 -10 days after CT simulation. Because CT-2 for boost IMRT plan was performed at an RT dose of 36 -40 Gy, no treatment interruption due to treatment planning was inserted for all patients. A two-step IMRT method has an advantage, in that it can adapt the treatment to changes in body contour, target volumes and risk organs during IMRT. As patients with locally advanced NPC frequently appeared with large neck lymph nodes swelling and as both primary tumors and neck lymph nodes regress rapidly by RT, a two-step IMRT method is especially desirable for locally advanced NPC. In the only other report of a two-step IMRT method, Lee et al. (13) described a Phase I/II study of a two-step SIB method for 20 patients with NPC.
No direct comparison in terms of clinical or DVH results between a single-step and a two-step IMRT was shown in the present study, because all patients with NPC were treated with a two-step IMRT method at our institution. We do not argue a two-step IMRT method is a new standard method of IMRT. A two-step method has been used in the conventional RT for head and neck cancer. Thus, a two-step IMRT method is a conventional and conservative method of IMRT compared with a single-step SIB IMRT method with larger fraction sizes for GTV. For early-stage NPC with T1,2N0M0 disease, effects of tumor regression during IMRT may be small, and a single-step method may be applicable. In fact, a single-step SIB IMRT method is applied for early oropharyngeal cancer (T1,2N0,1M0) at our institution. However, even for patients with early NPC, body weight and contour can be changed when concurrent CRT is used. Therefore, we consider that a two-step IMRT method is one of the safe methods of IMRT for patients with NPC treated by concurrent CRT.
In our early cases, PTV marginal recurrence was noted in three patients (9%). There may be several reasons for the early marginal recurrence. In our first TPS (Cadplan Helios), the function of adding a margin to CTV or GTV was lacking, i.e. PTV was contoured directly at that time (Figs 3  and 4) . In two of the three patients with marginal recurrences, pre-treatment MRI or CT scan of the patients could depict the involved nodes or the extension of the primary tumor. Precise contouring of CTV and PTV based on various imaging modalities including MRI and FDG-PET is most important for the success of IMRT. TPS was changed to the second generation type (Eclipse) in 2004 and PTV margins of 3 -5 mm were added to CTV (28) . In addition, an integrated PET-CT simulation was started in 2006 (22, 23) . PET-CT simulation was especially effective to depict GTV invading the skull base. Along with improvements in equipment and knowledge of contouring, PTV marginal recurrence has never occurred since 2003.
Only six patients (18%) complained of Grade 2 or 3 xerostomia 1 -2 years after IMRT. Thus, a two-step IMRT is also effective for preventing xerostomia. One notable late toxicity is dysphagia. Recently, several investigators have noted the importance of the RT dose to the pharyngeal constructors (30 -32) . Seven patients complained of Grade 1 or 2 dysphagia, and one patient died of suffocation by food 
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A two-step IMRT method for NPC 3 months after the end of IMRT without evidence of the disease. As this patient had complained of dysphagia, this accident may have been a treatment-related death (Grade 5 toxicity).
In conclusion, excellent overall survival and local-PFS rates were obtained by a two-step IMRT method with concurrent chemotherapy for NPC. This two-step IMRT method as an adaptive RT scheme could correspond to changes in body contour, target volumes and risk organs during IMRT. A prospective multi-institutional clinical trial of a two-step IMRT method for NPC is warranted.
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